Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
Vicarious Surgical Inc. reports developments tied to its robotic surgery technology, financial results, and public-company status. The company is developing the Vicarious Surgical System for minimally invasive surgery, with updates covering benchtop and in-vivo testing, surgical instruments for ventral hernia repair, software engineering support, and progress toward system validation and clinical readiness.
Company news also covers operating expense trends, research and development spending, cash-burn discipline, and capital markets actions involving its Class A common stock. Recent disclosures include quotation on the OTCQB market after NYSE suspension and filings related to stockholder approval of a potential reverse stock split.
Vicarious Surgical (OTCQB: RBOT) reported a full-day synthetic abdominal model lab for the Vicarious Surgical System, showing sustained system performance and complex ventral hernia procedure workflows (IPOM+ and rTAPP) using its integrated instrument suite.
The testing extended prior benchtop work into clinically relevant conditions, with progress in runtime stability, visualization, instrument control and workflow execution. The company reiterates it remains on track for a design freeze by end of 2026 and plans further cadaveric and in-vivo studies.
Vicarious Surgical (OTCQB: RBOT) reported first quarter 2026 results for the period ended March 31, 2026. Total operating expenses were $7.5 million, down 52% year-over-year. R&D was $5.0 million (-46%), G&A $2.1 million (-60%), and sales and marketing $0.3 million (-67%). Net loss was $7.3 million, or $1.03 per share, versus a $15.4 million loss ($2.60 per share) in Q1 2025. The company continues to expect full-year 2026 cash burn of approximately $19 million.
Vicarious Surgical (OTCQB: RBOT) completed integrated benchtop testing of its full surgical instrument suite for ventral hernia repair, validating needle drivers, fenestrated graspers, and monopolar scissors in a unified system evaluation.
Instrument and camera sensors remained stable under monopolar electrosurgical energy, supporting the company’s move toward design freeze and planned preclinical cadaveric and porcine studies.
Vicarious Surgical (OTCQB: RBOT) announced its Class A common stock began quotation on the OTCQB on March 24, 2026, marking a step in its capital markets strategy toward a potential Nasdaq Capital Market listing.
The company said trading on the OTCQB could improve market visibility, attract market maker participation, and support liquidity as it advances operational milestones, including a targeted design freeze by the end of 2026.
Vicarious Surgical (OTCID: RBOT) announced strategic actions to strengthen finances and pursue a Nasdaq relisting. The company expects 2026 cash burn of approximately $19 million (down from ~$35M guidance and ~$50M mid-2025), believes cash runway extends through Q2 2026, and targets system design freeze by year-end 2026. It filed a Nasdaq listing application, a preliminary proxy to authorize a reverse stock split, and an OTCQB upgrade application while exploring capital raises.
Vicarious Surgical (OTCID: RBOT) reported Q4 and full-year 2025 results, showing reduced operating expenses and narrower losses. Total operating expenses were $9.3M in Q4 2025 and $50.0M for full year 2025, down 38% and 25% respectively versus prior periods. Cash and investments were $9.8M at year-end, full-year 2025 cash burn was $45.1M, below prior guidance, and the company expects approximately $19M cash burn for 2026.
Vicarious Surgical (NYSE: RBOT) received a delisting notice from the NYSE on March 3, 2026 after trading was suspended following market close.
The NYSE determined the company fell below the continued listing standard requiring a $15,000,000 average global market capitalization over 30 trading days. The company has ten business days to appeal and expects quotation on OTCID under symbol RBOT beginning March 4, 2026.
Vicarious Surgical (NYSE: RBOT) completed a successful in-vivo porcine lab in December 2025, advancing development of its robotic system and supporting progress toward a targeted system design freeze by end of 2026. Surgeons independently completed key elements of an intraperitoneal onlay mesh (IPOM) ventral hernia repair using the pre-DV system. The lab included three protocols: IPOM feasibility, monopolar scissors energy/cautery evaluation, and visualization and imaging assessments.
Data and structured surgeon feedback from the realistic in-vivo setting are being used for design refinement, verification planning, and system optimization. The lab was for research and development purposes only and was not designed to support regulatory submissions or clinical claims.
Vicarious Surgical (NYSE: RBOT) announced a strategic software execution partnership on December 29, 2025 to streamline operations and accelerate product development. The company has entered into an agreement with a global digital engineering and software development services firm to assume responsibility for a significant portion of software development supporting the Vicarious robotic system, including control systems, visualization, and key workflow components.
The partnership is presented as a core element of an operating model transformation intended to increase development velocity, improve milestone predictability, and reduce operating expenses and cash burn through a hybrid mix of internal and external engineering resources. Onboarding has begun via a structured transition plan to maintain continuity across active workstreams.
Vicarious Surgical (NYSE: RBOT) provided full‑year 2026 cash burn guidance of approximately $35 million, a $10 million improvement versus its updated 2025 guidance of $45 million. The company said cash needs beyond existing resources to achieve design freeze on the Vicarious Surgical system are approximately $25 million. Management attributed the improved guidance to an operational reset, including reductions in headcount and external consulting spend, partially offset by increased use of strategic outsourcing to meet critical development milestones. The company reiterated its target of achieving design freeze by year‑end 2026.